OJEMDA TM (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Exhibit 99.1 Day One Reports First Quarter 2025 Financial Results and Corporate Progress Achieved Q1 2025 OJEMDA TM (tovorafenib) net product revenue of $30.5 million Ended the first quarter with$473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 6, 2025 – Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the " ...